AstraZeneca Voluntarily Recalls One Lot of Nexium
AstraZeneca has initiated a voluntary Class II recall of 34,524 bottles of Nexium (esomeprazole magnesium), delayed-release capsules, 20 mg, 30-count bottle, prescription only, manufactured for AstraZeneca LLC, Wilmington, Delaware and distributed by AstraZeneca, AB, Sodertalje, Sweden. The recall was initiated due to the presence of foreign tablets/capsules from a confimed customer compliant by a retail pharmacist that an unopened bottle labeled as Nexium capsules contained 60 Seroquel XR tablets.
The recall, which was reported in the US Food and Drug Administration’s Weekly Enforcement Report of June 24, 2015, was initiated on June 10, 2015 and applies nationwide in the US to wholesalers for further distribution at the retail level. The recall involves one affected lot.
A Class II recall is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.